Constance A. Benson, MD

Editor, Topics in Antiviral Medicine, IAS–USA
Professor of Medicine
Divisions of Infectious Diseases and Global Public Health
I.D. Training Program Director
Director, Antiviral Research Center
PI/Director, HIV/AIDS Clinical Trials Unit
University of California San Diego
San Diego, California


Committees and Organizations

  • Fellow, American College of Physicians (1985-)
  • Fellow, Infectious Disease Society of America (1989-)
  • Member, International Antiviral Society (1997-)
  • Member, Board of Directors, IAS–USA (1997-)
  • Member, Metabolic Complications Guidelines Panel, IAS–USA
  • Member, Board of Directors, Foundation for Human Retrovirology (1997-)

Honors and Awards

  • Outstanding Medical Resident Award, Rush Medical College (1981)
  • Constance B. Wofsy Women’s Health Investigator Award, NIH/NIAID/AIDS Clinical Trials Group (1996)

Education

  • Ohio State University, BS, Cum Laude, Zoology (1970-1975)
  • Ohio State University College of Medicine, MD, Cum Laude with Honors (1975-1978)
  • Rush Medical College/Rush-Presbyterian-St. Luke’s Medical Center, Fellowship in Infectious Diseases (1984-1986)
  • Rush Medical College/Rush-Presbyterian-St. Luke’s Medical Center, Internship/Residency, Categorical Internal Medicine (1978-1981)

Selected Publications

  1. Benson CA. Treatment of disseminated disease due to the Mycobacterium avium complex in patients with AIDS. Clin Infect Dis. 1994;18:S237-S242.
  2. Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkiun S, Smith T, Craft JC, Sattler FR, and the AIDS Clinical Trials Group Protocol 157 Study Team. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med. 1994;121:905-911.
  3. Sha BE, Benson CA, Pottage JC Jr, Urbanski PA, Daugherty SR, Kessler HA. HIV infection in women: an observational study of clinical characteristics, disease progression, and survival for a cohort of women in Chicago. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:486-495.
  4. Ellis LC, Benson CA, Koenig GI, Trenholme GM. Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex. Antimicrob Agents Chemother. 1995; 39:2803-2806.
  5. Sha BE, D’Amico RD, Landay AL, Spear GT, Massad LS, Warner NA, Rydman RJ, Padnick J, Ackatz L, Charles LA, Benson CA. Evaluation of immunologic markers in cervicovaginal fluid of HIV-infected and uninfected women: implications for the immunologic response to HIV in the female genital tract. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:161-168.
  6. Spear GT, Sha BE, Saarloos MN, Benson CA, Rydman R, Massad LS, Gilmore R, Landay A. Chemokines are present in the genital tract of HIV-seropositive and seronegative women; correlation with clinical conditions and other immune mediators. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:454-459.
  7. Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, Korvick JA, Heifets L, Child CC, Lederman MM, Reichman RC, Powderly WG, Notario GF, Wynne BA, Hafner R. Clarithromycin or rifabutin alone or in combination for the primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. J Infect Dis. 2000;181:1289-1297.
  8. Currier JS, Williams PL, Koletar SL, Benson CA, Valdez H, Aberg JA, and McCutchan A, for the ACTG 362 Study Team (11th author). Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;133:493-503.
  9. Johnson SC, Benson CA, Johnson DW, Weinberg A. Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. Clin Infect Dis. 2001;32:815-819.
  10. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White AC Jr, Benson C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15:F1-F9.